Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.

Inclusion Criteria:

* Histologically confirmed diagnosis of RCC with clear cell component
* Measurable disease
* Treated with up to 6 prior systemic therapies for advanced/recurrent disease or have become intolerant to a systemic therapy
* Subjects with treated brain metastases must be without magnetic resonance imaging (MRI) evidence of progression for at least 8 weeks and off steroids for at least 4 weeks to be eligible
* At least 28 days since the last chemotherapy
* At least 28 days before the first dose of MDX 1411 since any major surgery
* ECOG performance status 0-2
* No known positivity for human immunodeficiency virus (HIV), Hep B or C

Exclusion Criteria:

* Previous treatment with any other anti-CD70 antibody
* Active infection requiring i.v systemic therapy within 28 days before first dose
* Evidence of bleeding diathesis or coagulopathy
* Active autoimmune disease requiring immunosuppressive therapy
* Known current drug or alcohol abuse
* Any underlying medical condition which will make the administration of MDX 1411 hazardous
* Psychiatric illness or social situation that would preclude study compliance